The purpose of this article is to highlight ways in which institutional policymakers tend to insufficiently conceptualise their role as ethics practitioners. We use the case of blood product recall notification as a means of raising questions about the way in which, as we have observed it, discourse for those who make institutional ethics policies is constrained by routine balancing of simplified principles to the exclusion of reflexive practices—those that turn ethics reasoning back on itself. The latter allows ethics practitioners with comparatively little formal training to take ownership of traditional parameters, which define their discussions and ultimately ought to make them more insightful when doing ethics. Thus, in the midst of calls for more training to increase the competency of ethics committees, we suggest that an additional problem of how these lay ethicists conceive of their roles also needs to be addressed.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: None.
Read the full text or download the PDF:
Other content recommended for you
- Should men who have ever had sex with men be allowed to give blood? Yes
- Towards an appropriate ethics framework for Health and Demographic Surveillance Systems (HDSS): learning from issues faced in diverse HDSS in sub-Saharan Africa
- US lifts 30 year ban and allows some gay men to donate blood
- Gaps, conflicts, and consensus in the ethics statements of professional associations, medical groups, and health plans
- Payment in challenge studies: ethics, attitudes and a new payment for risk model
- Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Can we accredit hospital ethics? A tentative proposal
- Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment